Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Return on Sales (2016 - 2025)

Perspective Therapeutics' Return on Sales history spans 16 years, with the latest figure at 1.67% for Q3 2025.

  • For Q3 2025, Return on Sales rose 6.0% year-over-year to 1.67%; the TTM value through Sep 2025 reached 1.67%, up 6.0%, while the annual FY2024 figure was 0.67%, 564.0% up from the prior year.
  • Return on Sales for Q3 2025 was 1.67% at Perspective Therapeutics, up from 0.85% in the prior quarter.
  • Across five years, Return on Sales topped out at 1.67% in Q3 2025 and bottomed at 2.37% in Q3 2022.
  • The 5-year median for Return on Sales is 0.46% (2022), against an average of 0.41%.
  • The largest annual shift saw Return on Sales soared 257bps in 2023 before it tumbled -173bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 0.12% in 2021, then crashed by -1387bps to 1.51% in 2022, then soared by 170bps to 1.06% in 2023, then tumbled by -164bps to 0.67% in 2024, then surged by 348bps to 1.67% in 2025.
  • Per Business Quant, the three most recent readings for CATX's Return on Sales are 1.67% (Q3 2025), 0.85% (Q2 2025), and 0.44% (Q1 2025).